These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 21906252)
1. Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation. Gala-Lopez BL; Senior PA; Koh A; Kashkoush SM; Kawahara T; Kin T; Humar A; Shapiro AM Am J Transplant; 2011 Dec; 11(12):2708-14. PubMed ID: 21906252 [TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus viremia in lung transplantation during and after prophylaxis. Chang A; Musk M; Lavender M; Wrobel J; Yaw MC; Lawrence S; Chirayath S; Boan P Transpl Infect Dis; 2019 Jun; 21(3):e13069. PubMed ID: 30884067 [TBL] [Abstract][Full Text] [Related]
3. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial. Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M; Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954 [TBL] [Abstract][Full Text] [Related]
4. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Humar A; Kumar D; Preiksaitis J; Boivin G; Siegal D; Fenton J; Jackson K; Nia S; Lien D Am J Transplant; 2005 Jun; 5(6):1462-8. PubMed ID: 15888055 [TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR Am J Transplant; 2010 Jan; 10(1):157-61. PubMed ID: 19889123 [TBL] [Abstract][Full Text] [Related]
6. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study. Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441 [TBL] [Abstract][Full Text] [Related]
7. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts. Singh N; Wannstedt C; Keyes L; Mayher D; Tickerhoof L; Akoad M; Wagener MM; Cacciarelli TV Liver Transpl; 2008 Feb; 14(2):240-4. PubMed ID: 18236404 [TBL] [Abstract][Full Text] [Related]
8. Lack of cytomegalovirus transmission after pancreatic islet transplantation. Barshes NR; Lee TC; Brunicardi FC; Mote A; Schock AP; Alejandro R; Ricordi C; Goss JA Cell Transplant; 2004; 13(7-8):833-8. PubMed ID: 15690986 [TBL] [Abstract][Full Text] [Related]
9. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients. Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146 [TBL] [Abstract][Full Text] [Related]
10. A polymorphism linked to elevated levels of interferon-γ is associated with an increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center. Mitsani D; Nguyen MH; Girnita DM; Spichty K; Kwak EJ; Silveira FP; Toyoda Y; Pilewski JM; Crespo M; Bhama JK; Abdel-Massih R; Zaldonis D; Zeevi A; Clancy CJ J Heart Lung Transplant; 2011 May; 30(5):523-9. PubMed ID: 21239188 [TBL] [Abstract][Full Text] [Related]
11. Impact of donor and recipient cytomegalovirus serology on long-term survival of heart transplant recipients. Mabilangan C; Preiksaitis JK; Cervera C; Transpl Infect Dis; 2019 Feb; 21(1):e13015. PubMed ID: 30358023 [TBL] [Abstract][Full Text] [Related]
13. Three cases of cytomegalovirus infection following pancreatic islet transplantation. Yakubovich N; Fung MA; Thompson DM Transplant Proc; 2007 Jun; 39(5):1599-603. PubMed ID: 17580197 [TBL] [Abstract][Full Text] [Related]
14. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease. Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661 [TBL] [Abstract][Full Text] [Related]
15. A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R-) solid organ transplant recipients. San Juan R; Yebra M; Lumbreras C; López-Medrano F; Lizasoain M; Meneu JC; Delgado J; Andrés A; Aguado JM Clin Transplant; 2009; 23(5):666-71. PubMed ID: 19689451 [TBL] [Abstract][Full Text] [Related]
16. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients. Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269 [TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience. Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426 [TBL] [Abstract][Full Text] [Related]
19. Small bowel transplantation complicated by cytomegalovirus tissue invasive disease without viremia. Avsar Y; Cicinnati VR; Kabar I; Wolters H; Anthoni C; Schmidt HH; Beckebaum S J Clin Virol; 2014 Jun; 60(2):177-80. PubMed ID: 24703746 [TBL] [Abstract][Full Text] [Related]
20. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis. Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]